|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02607 SH PHARMA
Nominal 
13.000 +0.240 (+1.881%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 139,413,146 | 5.144% | 132,592,157 | 111,707,464 | 105,237,469 | 87,165,105 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (215,493) | 193.689% | (73,375) | (152,852) | (221,062) | (281,992) | |
| Profit / (Loss) on Disposal | 139,310 | 88.906% | 73,746 | 1,427,180 | 5,925 | (1,215) | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 365,613 | -- | (65,419) | 377,555 | 609,988 | 552,312 | |
| Profit / (Loss) before Taxation | 4,822,021 | 6.357% | 4,533,793 | 5,757,963 | 5,217,563 | 3,603,877 | |
| Taxation | (1,224,658) | 9.659% | (1,116,791) | (1,193,744) | (1,052,773) | (722,714) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (655,452) | -18.797% | (807,179) | (868,613) | (597,031) | (438,321) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,941,911 | 12.725% | 2,609,822 | 3,695,607 | 3,567,760 | 2,442,842 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 705,939 | -8.701% | 773,220 | 648,914 | 578,869 | 670,508 |
| Depreciation & Amortisation | 1,248,982 | 5.915% | 1,179,235 | 1,193,683 | 1,176,302 | 1,103,332 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 79.000 | 11.268% | 71.000 | 113.000 | 126.000 | 86.000 |
| DPS (cts) | 8.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | 10.127% | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 18.898 | -- | 18.189 | 17.674 | 16.789 | 15.102 |
| Remarks: | Real time quote last updated: 29/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,941,911 |
| %Change | 12.725% |
| EPS / (LPS) | RMB 0.790 |
| NBV Per Share (¥) | RMB 18.898 |